Patricia Ares-Romero

Oct 23, 2024 | managedhealthcareexecutive.com | Steven Levine |Patricia Ares-Romero |Carrie Jardine |Samuel Norberg |Maritn Rosenzweig

Steven Levine, MD: Before we conclude, I’d like to get some final thoughts from each of you, if you have any. Let’s start with you, Dr Nordberg. Samuel Nordberg, PhD: From my perspective, treatment-resistant depression and other complex mental health challenges are systems challenges as much as they are clinical challenges. We haven’t moved the needle in treatment effectiveness in about 50 years, and in no small respect that may be because we haven’t changed our systems that provide care.

Oct 23, 2024 | managedhealthcareexecutive.com | Steven Levine |Patricia Ares-Romero |Carrie Jardine |Samuel Norberg |Maritn Rosenzweig

Steven Levine, MD: How might a payer flag a patient who’s receiving a medication like intranasal esketamine [Spravato] that requires high touch to support access and reduce delay to therapy? What are some strategies that can be employed there? Martin Rosenzweig, MD: One thing that we have a lot of is data. We also have data that fits across episode and provider, or place of service. We have mechanisms by which we can track a member course.

Oct 15, 2024 | managedhealthcareexecutive.com | Steven Levine |Patricia Ares-Romero |Carrie Jardine |Samuel Norberg |Maritn Rosenzweig

Steven Levine, MD: Let’s go back to Dr Rosenzweig for another payer-focused question. Thinking about drugs or services like intranasal esketamine [Spravato], or perhaps other nonoral alternative therapies, and in the case where there might be a combination of a drug and some service delivery component, how do you ensure the policymaking for a drug and its evaluation and management and the service component attached are integrated?

Oct 15, 2024 | managedhealthcareexecutive.com | Steven Levine |Patricia Ares-Romero |Carrie Jardine |Samuel Norberg |Maritn Rosenzweig

Steven Levine, MD: Dr Rosenzweig, you mentioned this earlier. Sometimes, and often with intranasal esketamine [Spravato], some payers may require prior authorizations prior to approving administration of that therapy. Carrie, can you talk a bit about how payers’ differing prior authorization requirements can impact patient access? Carrie Jardine: Absolutely.

Sep 27, 2024 | managedhealthcareexecutive.com | Steven Levine |Patricia Ares-Romero |Carrie Jardine |Samuel Norberg |Maritn Rosenzweig

I’m Dr Steve Levine, cofounder and non-executive chairman of the board of Heading Health in Austin, Texas, and senior vice president of patient access and medical affairs for COMPASS Pathways. Joining me in this discussion are my colleagues Dr Patricia Ares-Romero, vice president and chief medical officer of My Psychiatrist in Miami, Florida;.